Published on: 15 December 2020 Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Switzerland for people with NTRK fusion-positive solid tumours and for people with ROS1 fusion-positive advanced non-small cell lung cancer more
Published on: 16 November 2020 Roche’s Tecentriq in combination with bevacizumab approved in Switzerland for people with the most common form of liver cancer more
Subscribe to Roche Media Releases for Switzerland Get the latest news and updates to your inbox. more
